PharmaPrint's saw palmetto-derived drug in Phase II for benign prostatic hypertrophy.
This article was originally published in The Tan Sheet
Executive Summary
PHARMAPRINT CONDUCTING SAW PALMETTO-DERIVED DRUG PHASE II TRIALS for treatment of benign prostatic hypertrophy (enlarged prostate) and will begin a Phase II study on a St. John's wort-derived drug for depression in December, PharmaPrint Chairman and CEO Elliott Friedman told securities analysts at the Wall Street Forum in New York City Oct. 2. The company has negotiated an "accelerated approval process" with FDA, under which trials for the drugs will begin in Phase II, Friedman reported.